These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
191 related items for PubMed ID: 17979493
1. Transformation of polycythemia vera to chronic myelogenous leukemia. Mirza I, Frantz C, Clarke G, Voth AJ, Turner R. Arch Pathol Lab Med; 2007 Nov; 131(11):1719-24. PubMed ID: 17979493 [Abstract] [Full Text] [Related]
8. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. Nagao T, Kurosu T, Umezawa Y, Nogami A, Oshikawa G, Tohda S, Yamamoto M, Miura O. PLoS One; 2014 Apr 08; 9(1):e84746. PubMed ID: 24404189 [Abstract] [Full Text] [Related]
9. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, Wang SA, Bueso-Ramos CE, Orazi A, Arber DA, Hexner EO, Babushok DV, Bagg A. Mod Pathol; 2018 May 08; 31(5):690-704. PubMed ID: 29327708 [Abstract] [Full Text] [Related]
10. Molecular genetic evaluation of myeloproliferative neoplasms. Azzato EM, Bagg A. Int J Lab Hematol; 2015 May 08; 37 Suppl 1():61-71. PubMed ID: 25976962 [Abstract] [Full Text] [Related]
12. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F. Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C. Arch Pathol Lab Med; 2014 Sep 08; 138(9):1203-9. PubMed ID: 25171702 [Abstract] [Full Text] [Related]
13. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge. Shaikh AB, Aribandi A, Gupta A, Subramanian SK, Goyal M. Indian J Pathol Microbiol; 2021 Sep 08; 64(4):820-823. PubMed ID: 34673614 [Abstract] [Full Text] [Related]
14. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations. Turakhia SK, Murugesan G, Cotta CV, Theil KS. J Clin Pathol; 2016 Aug 08; 69(8):713-9. PubMed ID: 26754830 [Abstract] [Full Text] [Related]
15. [Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia]. Jomen W, Kuroda H, Matsuno T, Sato M, Yamada M, Abe T, Sakurai T, Fujii S, Maeda M, Fujita M, Kato J, Nojiri S. Rinsho Ketsueki; 2014 Mar 08; 55(3):360-5. PubMed ID: 24681942 [Abstract] [Full Text] [Related]
16. The role of beta-catenin in chronic myeloproliferative disorders. Jauregui MP, Sanchez SR, Ewton AA, Rice L, Perkins SL, Dunphy CH, Chang CC. Hum Pathol; 2008 Oct 08; 39(10):1454-8. PubMed ID: 18619646 [Abstract] [Full Text] [Related]